SGLT-2 inhibitors decrease serum FGF21 level in quinquagenarian diabetic patients

doi:10.3877/cma.j.issn.2095-8757.2023.03.006

Abstract

Abstract:

Objective

To explore the effects of sodium glucose co-transporter-2 inhibitor (SGLT2i) on the serum levels of fibroblast growth factor 21 (FGF21) in quinquagenarian diabetic patients.

Methods

Study was performed in 54 patients with type 2 diabetes in Zhejiang Hospital during October 2021 and February 2023. All patients aged over 50 years, including 28 patients treated with metformin (control group) and 26 patients treated with metformin and SGLT2i (experimental group). Diabetic course, body mass index, hemoglobin A1C, fasting blood glucose, fasting C-peptide, low density lipoprotein, triglycerides, high density lipoprotein, total cholesterol, uric acid, creatinine and serum FGF21 level were collected. Independent t test was applied for between-group analysis, and multiple linear regression was used to identify the independent influencing factors of serum FGF21 levels.

Results

Diabetic course was higher in experimental group than that in the control group (t=-4.650, P < 0.01), while uric acid and serum FGF21 level were lower than those in the control group (t=2.645 and 4.399, P < 0.05 or P < 0.01). Logistic regression analysis revealed that SGLT2i inhibitors therapy was independent risk factor for serum FGF21 level (t=-2.260, P < 0.05).

Conclusion

SGLT2i therapy was related with decreased serum FGF21 levels in quinquagenarian diabetic patients.

Key words: Sodium glucose co-transporter 2 inhibitors, Diabetes mellitus, type 2, Fibroblast growth factor 21

Xiaopei Chen, Dan Yu, Jun Pan, Jiachao Kong, Huan Li, Tianfeng Wu. SGLT-2 inhibitors decrease serum FGF21 level in quinquagenarian diabetic patients[J]. Chinese Journal of Geriatrics Research(Electronic Edition), 2023, 10(03): 35-38.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlnbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-8757.2023.03.006

https://zhlnbyjdzzz.cma-cmc.com.cn/EN/Y2023/V10/I03/35

Figures/Tables 3

References 14

[1]	Chavda V, Vashi R, Patel S. Cerebrovascular complications of diabetes: SGLT-2 inhibitors as a promising future therapeutics[J]. Curr Drug Targets, 2021, 22(14):1629-1636.
[2]	Marilly E, Cottin J, Cabrera N, et al. SGLT2 inhibitors in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits[J]. Diabetologia, 2022, 65(12):2000-2010.
[3]	Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: Collaborative meta-analysis of large placebo-controlled trials[J]. Lancet, 2022, 400(10365):1788-1801.
[4]	Flippo KH, Potthoff MJ. Metabolic messengers: FGF21[J]. Nat Metab, 2021, 3(3):309-317.
[5]	Tan H, Yue T, Chen Z, et al. Targeting FGF21 in cardiovascular and metabolic diseases: From mechanism to medicine[J]. Int J Biol Sci, 2023, 19(1):66-88.
[6]	Chen Z, Yang L, Liu Y, et al. The potential function and clinical application of FGF21 in metabolic diseases[J]. Front Pharmacol, 2022, 13:1089214.
[7]	中国老年2型糖尿病防治临床指南编写组，中国老年医学学会老年内分泌代谢分会，中国老年保健医学研究会老年内分泌与代谢分会，等.中国老年2型糖尿病防治临床指南（2022年版）[J].中华内科杂志，2022，61（1）：12-50.
[8]	Shi Q, Nong K, Vandvik PO, et al. Benefits and harms of drug treatment for type 2 diabetes: Systematic review and network meta-analysis of randomised controlled trials[J/OL]. BMJ, 2023, 381:e074068.
[9]	Szczepańska E, Gietka-Czernel M. FGF21: A novel regulator of glucose and lipid metabolism and whole-body energy balance[J]. Horm Metab Res, 2022, 54(4):203-211.
[10]	Osataphan S, Macchi C, Singhal G, et al. SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms[J/OL]. JCI Insight, 2019, 4(5):e123130.
[11]	Huang S, Wu B, He Y, et al. Canagliflozin ameliorates the development of NAFLD by preventing NLRP3-mediated pyroptosis through FGF21-ERK1/2 pathway[J/OL]. Hepatol Commun, 2023, 7(3):e0045.
[12]	Yamakage H, Tanaka M, Inoue T, et al. Effects of dapagliflozin on the serum levels of fibroblast growth factor 21 and myokines and muscle mass in Japanese patients with type 2 diabetes: A randomized, controlled trial[J]. J Diabetes Investig, 2020, 11(3):653-661.
[13]	Kosugi R, Nakatani E, Okamoto K, et al. Effects of sodium-glucose cotransporter 2 inhibitor (dapagliflozin) on food intake and plasma fibroblast growth factor 21 levels in type 2 diabetes patients[J]. Endocr J, 2019, 66(8):677-682.
[14]	Yan H, Xia M, Chang X, et al. Circulating fibroblast growth factor 21 levels are closely associated with hepatic fat content: A cross-sectional study[J]. PLoS One, 2011, 6(9):e24895.

组别	例	年龄（岁）	糖尿病病程（年）	体质指数（kg/m²）	HbA1c（%）	空腹血糖（mmol/L）	血清C肽（pmol/L）	肌酐（μmol/L）
对照组	28	63.1±9.7	6.8±5.9	25.3±2.8	8.3±2.4	7.6±1.0	794.7±281.2	78.2±17.9
观察组	26	63.2±7.1	14.8±6.7	26.3±2.6	9.0±1.0	8.4±2.3	553.2±473.1	81.2±21.5
t值		-0.005	-4.650	-0.791	-0.908	-0.978	1.161	-0.321
P值		>0.05	<0.01	>0.05	>0.05	>0.05	>0.05	>0.05
组别	例	血尿酸（μmol/L）	三酰甘油（mmol/L）	总胆固醇（mmol/L）	HDL（mmol/L）	LDL（mmol/L）	FGF21（pg/mL）
对照组	28	371.3±96.6	2.1±1.7	4.8±1.5	1.0±0.2	2.8±1.1	17.5±5.3
观察组	26	375.9±73.8	2.2±0.7	4.7±0.9	1.0±0.1	2.8±0.4	15.1±6.6
t值		-0.112	-0.295	0.043	-0.408	-0.026	0.848
P值		>0.05	>0.05	>0.05	>0.05	>0.05	>0.05

组别	例	年龄（岁）	糖尿病病程（年）	体质指数（kg/m²）	HbA1c（%）	空腹血糖（mmol/L）	血清C肽（pmol/L）	肌酐（μmol/L）
对照组	28	63.1±9.7	6.8±5.9	25.3±2.8	8.3±2.4	7.6±1.0	794.7±281.2	78.2±17.9
观察组	26	63.2±7.1	14.8±6.7	26.3±2.6	9.0±1.0	8.4±2.3	553.2±473.1	81.2±21.5
t值		-0.005	-4.650	-0.791	-0.908	-0.978	1.161	-0.321
P值		>0.05	<0.01	>0.05	>0.05	>0.05	>0.05	>0.05
组别	例	血尿酸（μmol/L）	三酰甘油（mmol/L）	总胆固醇（mmol/L）	HDL（mmol/L）	LDL（mmol/L）	FGF21（pg/mL）
对照组	28	371.3±96.6	2.1±1.7	4.8±1.5	1.0±0.2	2.8±1.1	17.5±5.3
观察组	26	375.9±73.8	2.2±0.7	4.7±0.9	1.0±0.1	2.8±0.4	15.1±6.6
t值		-0.112	-0.295	0.043	-0.408	-0.026	0.848
P值		>0.05	>0.05	>0.05	>0.05	>0.05	>0.05

组别	例	体质指数（kg/m²）	HbA1c（%）	空腹血糖（mmol/L）	血清C肽（pmol/L）	肌酐（μmol/L）	血尿酸（μmol/L）
对照组	28	24.7±2.5	8.2±2.5	7.6±1.4	731.2±345.4	74.2±17.0	374.9±97.5
观察组	26	25.4±2.7	7.9±1.1	7.5±1.9	611.7±343.9	77.9±19.4	314.5±66.1
t值		-0.989	0.614	0.379	1.013	-0.742	2.645
P值		>0.05	>0.05	>0.05	>0.05	>0.05	<0.05
组别	例	三酰甘油（mmol/L）	总胆固醇（mmol/L）	HDL（mmol/L）	LDL（mmol/L）	FGF21（pg/mL）
对照组	28	2.0±1.8	4.6±1.3	1.1±0.2	2.5±1.0	17.0±11.1
观察组	26	1.5±0.7	4.2±0.9	1.1±0.2	2.3±0.7	6.5±5.7
t值		1.153	1.630	0.402	1.009	4.399
P值		>0.05	>0.05	>0.05	>0.05	<0.01

组别	例	体质指数（kg/m²）	HbA1c（%）	空腹血糖（mmol/L）	血清C肽（pmol/L）	肌酐（μmol/L）	血尿酸（μmol/L）
对照组	28	24.7±2.5	8.2±2.5	7.6±1.4	731.2±345.4	74.2±17.0	374.9±97.5
观察组	26	25.4±2.7	7.9±1.1	7.5±1.9	611.7±343.9	77.9±19.4	314.5±66.1
t值		-0.989	0.614	0.379	1.013	-0.742	2.645
P值		>0.05	>0.05	>0.05	>0.05	>0.05	<0.05
组别	例	三酰甘油（mmol/L）	总胆固醇（mmol/L）	HDL（mmol/L）	LDL（mmol/L）	FGF21（pg/mL）
对照组	28	2.0±1.8	4.6±1.3	1.1±0.2	2.5±1.0	17.0±11.1
观察组	26	1.5±0.7	4.2±0.9	1.1±0.2	2.3±0.7	6.5±5.7
t值		1.153	1.630	0.402	1.009	4.399
P值		>0.05	>0.05	>0.05	>0.05	<0.01

变量	B值	标准差	标准系数	t值	P值
截距	28.765	7.057	-	4.076	<0.01
血尿酸	-0.005	0.014	-0.039	-0.326	>0.05
糖尿病病程	-0.529	0.184	-0.383	-2.866	<0.01
是否使用SGLT2i	-6.429	2.873	-0.318	-2.260	<0.05

Please choose a citation manager

Content to export